Stay updated on ALXN1210 vs Eculizumab in PNH Clinical Trial
Sign up to get notified when there's something new on the ALXN1210 vs Eculizumab in PNH Clinical Trial page.

Latest updates to the ALXN1210 vs Eculizumab in PNH Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.2 has been added and Revision: v3.4.1 has been removed. This appears to be a minor administrative update with no changes to study design or participant information.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; no changes to study data or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedGlossary toggle options (Show glossary / Hide glossary) are now visible, and the page includes updated QC metadata (Last Update Submitted that Met QC Criteria), a No FEAR Act Data notice, and a revision tag (v3.4.0).SummaryDifference0.2%

- Check41 days agoChange DetectedRevision: v3.3.4 added and the prior Revision: v3.3.3 removed, indicating a small technical update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded a Location section including California, Texas, Alberta, and Ontario, and updated the page revision to v3.3.3. Removed the HHS Vulnerability Disclosure item.SummaryDifference0.3%

- Check92 days agoChange DetectedPublications notes were updated to state that entries are automatically filled from PubMed and may not pertain to the study, and a Revision: v3.3.2 tag was added. The deletions were adjusted to reflect the same PubMed auto-fill wording, indicating this is a cosmetic update with no change to study data.SummaryDifference0.1%

Stay in the know with updates to ALXN1210 vs Eculizumab in PNH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALXN1210 vs Eculizumab in PNH Clinical Trial page.